Therapy-Related Myeloid Neoplasms Identified as Long-Term Risk for Breast and Ovarian Cancer Survivors

Recent advancements in the diagnosis and treatment of female-specific cancers, including breast and ovarian cancer, have led to significant improvements in survival rates. However, researchers have identified a serious long-term complication associated with these treatments: therapy-related myeloid neoplasms (t-MN). These secondary malignancies include therapy-related acute myeloid leukemia (t-AML) and myelodysplastic syndromes (t-MDS), which are linked to prior exposure to chemotherapy or radiation therapy.

Therapy-related myeloid neoplasms are considered rare but highly aggressive conditions that can develop years after successful cancer treatment. Studies indicate that the risk of t-MN is particularly pronounced among survivors of breast and ovarian cancers due to the intensive therapies often required for these diseases. The emergence of t-MN highlights the need for ongoing monitoring of cancer survivors, even after remission has been achieved. Researchers continue to investigate strategies for reducing this risk while balancing effective treatment options for primary cancers.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 2, 2026

Author

GOAI